In vivo programming of endogenous T-cells to induce transient CAR-expression ( in vivo CAR-Ts) could be a potential alternative to exogenously administered autologous and allogeneic cell therapies, which inherently possess several limitations such as logistical/financial constraints and graft v...
Page:
of
17